Article
Oncology
Jesus Gonzalez-Bosquet, S. John Weroha, Jamie N. Bakkum-Gamez, Amy L. Weaver, Michaela E. McGree, Sean C. Dowdy, Abimbola O. Famuyide, Benjamin R. Kipp, Kevin C. Halling, Siddhartha Yadav, Fergus J. Couch, Karl C. Podratz
Summary: A molecular classification system based on E2F1 and CCNA2 expression and sequence variations in POLE, PPP2R1A, or FBXW7 effectively stratifies MSI-H/NSMP EC and helps predict prognosis. In addition, neoadjuvant chemotherapy enhances therapeutic efficacy in high-risk MSI-H/NSMP EC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Masataka Takenaka, Misato Kamii, Yasushi Iida, Nozomu Yanaihara, Jiro Suzuki, Kazuaki Takahashi, Satoshi Yanagida, Motoaki Saito, Hirokuni Takano, Kyosuke Yamada, Aikou Okamoto
Summary: The study suggests that abnormal peritoneal cytology (PC) is an independent prognostic factor in endometrial cancer (EC) across different stages and tumor types. Early-stage EC patients with positive PC may have poorer progression-free survival and require careful management.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Cell Biology
Xin Fang, Nan Ni, Xiaofang Wang, Yanan Tian, Ivan Ivanov, Monique Rijnkels, Kayla J. Bayless, John P. Lydon, Qinglei Li
Summary: EZH2 has dual roles in the development of endometrial cancer, functioning as an oncogene in the early stages but also leading to unfavorable outcomes during disease progression, characterized by exacerbated epithelial stratification and heightened inflammatory response.
Article
Multidisciplinary Sciences
Bulat Zagidullin, Annukka Pasanen, Mikko Loukovaara, Ralf Butzow, Jing Tang
Summary: This study applies Cox proportional hazards and optimal survival tree algorithms to predict the survival of endometrial carcinoma patients, demonstrating the advantages of different models in risk assessment. The study also explores new research hypotheses using visual interpretable tree models and identifies important risk factors.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Xin Cheng, Xiaowei Wang, Kechao Nie, Lin Cheng, Zheyu Zhang, Yang Hu, Weijun Peng
Summary: TREM2 is highly expressed in most cancers and is associated with prognosis, tumor mutational burden, microsatellite instability, and DNA methylation. In 6 selected tumor types, TREM2 gene expression was negatively correlated with most immune cell infiltration levels but positively correlated with M1 and M2 macrophages infiltration levels. The correlation with TREM2 expression differed according to T cell subtype.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
C. Gomez-Raposo, M. Merino Salvador, C. Aguayo Zamora, B. Garcia de Santiago, E. Casado Saenz
Summary: The incidence of endometrial cancer is rising globally. Prognosis and treatment options vary for early-stage and recurrent/metastatic patients, where immune check-point inhibitors are showing promise, particularly for those with specific genetic markers.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Oncology
Claudia Mosillo, Maria Letizia Calandrella, Claudia Caserta, Serena Macrini, Annalisa Guida, Grazia Sirgiovanni, Sergio Bracarda
Summary: This review summarizes and discusses new therapeutic approaches for metastatic castration-resistant prostate cancer, including the prognostic and predictive role of molecular alterations, investigation techniques, and potential clinical implications. Despite the approval of several drugs, metastatic castration-resistant prostate cancer remains a lethal disease.
Article
Cell Biology
Mateusz Kozlowski, Dominika Pietrzyk, Malgorzata Rychlicka, Katarzyna Piotrowska, Katarzyna Nowak, Sebastian Kwiatkowski, Aneta Cymbaluk-Ploska
Summary: The study investigates the potential of vaspin as a prognostic and risk factor in endometrial cancer. It finds that higher levels of vaspin are associated with obesity and lower risk factors. Higher serum vaspin levels are identified as an independent protective factor for endometrial cancer. However, tissue expression of vaspin cannot be used as a histological marker to distinguish between cancerous and non-cancerous lesions.
Article
Oncology
Beryl L. Manning-Geist, Sonia Gatius, Ying Liu, Mabel Gil, Arnaud Da Cruz Paula, Noemi Tuset, Nadeem R. Abu-Rustum, Carol Aghajanian, Britta Weigelt, Xavier Matias-Guiu
Summary: The article presents a rare case of Cowden syndrome-associated endometrial carcinoma, discussing the clinical, pathological, and molecular features of the tumor, as well as predisposing inherited syndromes to endometrial carcinoma and PTEN-targeted therapies.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Yuanyuan Wang, Zhi Zhao, Jing Zhuang, Xinxin Wu, Zhizhong Wang, Bing Zhang, Ge Gao, Yinping Zhang, Caili Guo, Qingxin Xia
Summary: The high expression of the LC3 protein in CRC patients is associated with prognosis, and LC3, MSI status, and KRAS mutations are essential considerations in selecting adjuvant therapy for CRC. It helps to identify high-risk patients and explore more effective treatment options.
Article
Biology
Erling A. Hoivik, Erlend Hodneland, Julie A. Dybvik, Kari S. Wagner-Larsen, Kristine E. Fasmer, Hege F. Berg, Mari K. Halle, Ingfrid S. Haldorsen, Camilla Krakstad
Summary: Utilizing radiogenomic analysis in endometrial cancer patients, high-risk tumor features were identified along with an 11-gene high-risk signature that was validated for prognostic assessment and guiding treatment strategies.
COMMUNICATIONS BIOLOGY
(2021)
Article
Cell Biology
Meng Ding, Qiufang Li, Xiao Tan, Liangyua Zhang, Jun Tan, Lan Zheng
Summary: The pan-cancer analysis revealed that SPIB is upregulated in most cancers and associated with tumor prognosis, immune infiltration, immune checkpoint genes, and tumor mutational burden. Additionally, SPIB plays a role in NF-kappa B and B-cell receptor signaling pathways.
Review
Biochemistry & Molecular Biology
Roberto Piergentili, Simona Zaami, Anna Franca Cavaliere, Fabrizio Signore, Giovanni Scambia, Alberto Mattei, Enrico Marinelli, Caterina Gulia, Federica Perelli
Summary: Endometrial cancer classification is evolving to include genetic and epigenetic features, with noncoding RNAs emerging as promising prognostic markers in the field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Xiongjie Yu, Fengjun Cao, Yuandong Yu, Yong Li, Jun Zhang, Tao Xu, Quanshu Di, Guang Wu, Zhe Zhang, Ran Wang, Yanli Li
Summary: The study highlights the significantly increased expression of HNRNPL in MSI gastric cancer, with a significant negative correlation with MLH1 expression. High HNRNPL expression predicts poor prognosis in GC patients and is closely associated with biological functions such as inflammation and cell proliferation.
DNA AND CELL BIOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Xiao Yang, Yuan Cheng, Xingchen Li, Jingyi Zhou, Yangyang Dong, Boqiang Shen, Lijun Zhao, Jianliu Wang
Summary: By analyzing data from the TCGA database, a study developed and validated a prognostic signature based on nine transcription factors that accurately predict the prognosis of EC patients. The study also identified E2F1 as a potential target for the treatment of EC.
ONCOTARGETS AND THERAPY
(2021)
Correction
Cell Biology
Jian Carrot-Zhang, Xiaotong Yao, Siddhartha Devarakonda, Aditya Deshpande, Jeffrey S. Damrauer, Tiago Chedraoui Silva, Christopher K. Wong, Hyo Young Choi, Ina Felau, A. Gordon Robertson, Mauro A. A. Castro, Lisui Bao, Esther Rheinbay, Eric Minwei Liu, Tuan Trieu, David Haan, Christina Yau, Toshinori Hinoue, Yuexin Liu, Ofer Shapira, Kiran Kumar, Karen L. Mungall, Hailei Zhang, Jake June-Koo Lee, Ashton Berger, Galen F. Gao, Binyamin Zhitomirsky, Wen-Wei Liang, Meng Zhou, Sitapriya Moorthi, Alice H. Berger, Eric A. Collisson, Michael C. Zody, Li Ding, Andrew D. Cherniack, Gad Getz, Olivier Elemento, Christopher C. Benz, Josh Stuart, J. C. Zenklusen, Rameen Beroukhim, Jason C. Chang, Joshua D. Campbell, D. Neil Hayes, Lixing Yang, Peter W. Laird, John N. Weinstein, David J. Kwiatkowski, Ming S. Tsao, William D. Travis, Ekta Khurana, Benjamin P. Berman, Katherine A. Hoadley, Nicolas Robine, Matthew Meyerson, Ramaswamy Govindan, Marcin Imielinski
Article
Cell Biology
Jian Carrot-Zhang, Xiaotong Yao, Siddhartha Devarakonda, Aditya Deshpande, Jeffrey S. Damrauer, Tiago Chedraoui Silva, Christopher K. Wong, Hyo Young Choi, Ina Felau, A. Gordon Robertson, Mauro A. A. Castro, Lisui Bao, Esther Rheinbay, Eric Minwei Liu, Tuan Trieu, David Haan, Christina Yau, Toshinori Hinoue, Yuexin Liu, Ofer Shapira, Kiran Kumar, Karen L. Mungall, Hailei Zhang, Jake June-Koo Lee, Ashton Berger, Galen F. Gao, Binyamin Zhitomirsky, Wen-Wei Liang, Meng Zhou, Sitapriya Moorthi, Alice H. Berger, Eric A. Collisson, Michael C. Zody, Li Ding, Andrew D. Cherniack, Gad Getz, Olivier Elemento, Christopher C. Benz, Josh Stuart, J. C. Zenklusen, Rameen Beroukhim, Jason C. Chang, Joshua D. Campbell, D. Neil Hayes, Lixing Yang, Peter W. Laird, John N. Weinstein, David J. Kwiatkowski, Ming S. Tsao, William D. Travis, Ekta Khurana, Benjamin P. Berman, Katherine A. Hoadley, Nicolas Robine, Matthew Meyerson, Ramaswamy Govindan, Marcin Imielinski
Summary: Alterations in the RTK/RAS/RAF pathway are a characteristic feature of lung adenocarcinoma (LUAD). A study using whole-genome sequencing of 85 cases initially identified as RPA(-) revealed that around 33% of cases were actually RPA(+). The remaining cases showed genetic mutations associated with tumor suppressor deletions and genome instability.
Article
Oncology
Andrea S. Fung, Maryam Karimi, Stefan Michiels, Lesley Seymour, Elisabeth Brambilla, Thierry Le-Chevalier, Jean-Charles Soria, Robert Kratzke, Stephen L. Graziano, Siddhartha Devarakonda, Ramaswamy Govindan, Ming-Sound Tsao, Frances A. Shepherd
Summary: In early stage NSCLC, KRAS mutation with concomitant copy number aberrations may lead to worse prognosis, especially for KRAS MUT + Gain patients. However, in adenocarcinoma patients, there might be a potential predictive effect of concomitant KRAS mutation and copy number gain with adjuvant chemotherapy.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Meeting Abstract
Oncology
Sofia Genta, Ming Sound Tsao, Ben X. Wang, Aaron Richard Hansen, Trevor John Pugh, Mathieu Lupien, Bryan Coburn, Javier Diaz-Mejia, Marcus O. Butler, Philippe L. Bedard, Albiruni Ryan Abdul Razak, Sevan Hakgor, Vanessa Speers, Heidi Wagner, Laura Tamblyn, Troy Ketela, Dax Torti, Nikolina Radulovich, Lillian L. Siu, Anna Spreafico
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Carly C. Barron, Tracy Stockley, Jennifer H. Law, Muqdas Shabir, Roxanne Fernandes, Tong Zhang, Lisa W. Le, Ming Sound Tsao, Suzanne Kamel-Reid, Prodipto Pal, Michael Cabanero, Joerg Schwock, Hyangmi Ko, Geoffrey Liu, Penelope Ann Bradbury, Adrian G. Sacher, Frances A. Shepherd, Natasha B. Leighl, Kirstin Perdrizet
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Punit Saraon, Jamie Snider, Wiebke Schormann, Ankit Rai, Nikolina Radulovich, Maria Sanchez-Osuna, Jasmin Coulombe-Huntington, Caroline Huard, Mohammed Mohammed, Evelyne Lima-Fernandes, Brigitte Theriault, Levon Halabelian, Manuel Chan, Dhananjay Joshi, Luka Drecun, Zhong Yao, Shivanthy Pathmanathan, Victoria Wong, Anna Lyakisheva, Farzaneh Aboualizadeh, Li Niu, Fengling Li, Taira Kiyota, Ratheesh Subramanian, Babu Joseph, Ahmed Aman, Michael Prakesch, Methvin Isaac, Ahmed Mamai, Gennady Poda, Masoud Vedadi, Richard Marcellus, David Uehling, Natasha Leighl, Adrian Sacher, Miroslav Samarzija, Marko Jakopovic, Cheryl Arrowsmith, Mike Tyers, Ming-Sound Tsao, David Andrews, Rima Al-awar, Igor Stagljar
Summary: The small molecule EM166 was identified to inhibit mutant EGFR signalling and growth in NSCLC cells via a novel mechanism. EM166 affects the expression and signalling of certain proteins, alters subcellular localization, and modulates the ER stress response pathway in mutant EGFR lung cancer cells.
JOURNAL OF MOLECULAR BIOLOGY
(2021)
Editorial Material
Oncology
Ming-Sound Tsao, Andrew G. Nicholson, Joseph J. Maleszewski, Alexander Marx, William D. Travis
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Ku-Geng Huo, Hirotsugu Notsuda, Zhenhao Fang, Ningdi Feng Liu, Teklab Gebregiworgis, Quan Li, Nhu-An Pham, Ming Li, Ni Liu, Frances A. Shepherd, Christopher B. Marshall, Mitsuhiko Ikura, Nadeem Moghal, Ming-Sound Tsao
Summary: This study found that clinically approved EGFR TKIs can be used to treat patients with non-small cell lung cancer harboring the BRAF(G469V) mutation. Through experiments with a xenograft model and a cell line, it was confirmed that BRAF G469v is the oncogenic driver in this mutation. Structural modeling and experiments further demonstrated that BRAF(G469V) is a direct target of EGFR TKIs.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
Dalam Ly, Quan Li, Roya Navab, Cedric Zeltz, Linan Fang, Michael Cabanero, Chang-Qi Zhu, Ming-Sound Tsao, Li Zhang
Summary: Understanding how the immune system regulates the tumor microenvironment is crucial for the development of effective cancer treatments. This study reveals the adverse prognostic role of LAIR2 expression in regulatory T cells and identifies it as a potential target for future immunotherapies.
Article
Biochemistry & Molecular Biology
Cedric Zeltz, Maryam Khalil, Roya Navab, Ming-Sound Tsao
Summary: Collagen type XI restrains collagen remodeling and cell migration mediated by cancer-associated fibroblasts (CAF), thereby limiting the invasion of lung cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Joshua C. Rosen, Adrian Sacher, Ming-Sound Tsao
Summary: KRAS(G12C) inhibitors have shown promising results in clinical trials with overall response rates ranging between 32% and 46%, and have been granted FDA approvals as second-line or later monotherapies. However, rapid tumor resistance complicates their use as a monotherapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Shelley Kuang, Andrea S. Fung, Kirstin A. Perdrizet, Kaitlin Chen, Janice J. N. Li, Lisa W. Le, Michael Cabanero, Ola Abu Al Karsaneh, Ming S. Tsao, Josh Morganstein, Laura Ranich, Adam C. Smith, Cuihong Wei, Carol Cheung, Frances A. Shepherd, Geoffrey Liu, Penelope Bradbury, Prodipto Pal, Joerg Schwock, Adrian G. Sacher, Jennifer H. Law, Tracy L. Stockley, Natasha B. Leighl
Summary: In NSCLC patients, reflex testing using NGS panels can identify actionable genetic variants in the majority of cases with minimal increase in testing cost. Implementation of NGS panels is essential for the treatment of NSCLC patients as treatment paradigms continue to evolve.
Meeting Abstract
Medicine, Research & Experimental
Ellen Yang, Najd Alshamlan, Jessica Weiss, Michael Cabanero, Ming Tsao
LABORATORY INVESTIGATION
(2022)
Meeting Abstract
Oncology
Sally C. M. Lau, Shirin Soleimani, Jinfeng Zou, Justin Burgener, Shelley Kuang, Stephanie W. Y. Wong, Malcolm Ryan, Ben X. Wang, Stephanie Pedersen, Devalben Patel, Penelope A. Bradbury, Geoffrey Liu, Natasha Leighl, Ming S. Tsao, Pamela S. Ohashi, Scott V. Bratman, Trevor Pugh, Frances A. Shepherd, Adrian G. Sacher
Meeting Abstract
Oncology
A. C. L. Lam, R. Aggarwal, J. Huang, K. Hueniken, M. Tsao, F. Shepherd, W. Xu, J. Kavanagh, G. Liu
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)